167 related articles for article (PubMed ID: 7747363)
1. Clinical value of argyrophilic organizer region in bladder transitional cell carcinoma.
Shiina H; Shirakawa H; Yokogi H; Kishi H; Mizutani M; Igawa M; Ishibe T
Urol Int; 1995; 54(2):74-9. PubMed ID: 7747363
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the argyrophilic nucleolar organizer region, nuclear DNA content and mean nuclear area in transitional cell carcinoma of bladder using a quantitative image analyzer.
Shiina H; Urakami S; Shirakawa H; Shigeno K; Himeno Y; Mizutani M; Igawa M; Ishibe T
Eur Urol; 1996; 29(1):99-105. PubMed ID: 8821699
[TBL] [Abstract][Full Text] [Related]
3. Comparison of ureteropelvic transitional cell carcinoma with bladder transitional cell carcinoma using an image analyzer.
Shiina H; Igawa M; Urakami S; Shirakawa H; Ishibe T
Urol Int; 1996; 56(3):163-8. PubMed ID: 8860737
[TBL] [Abstract][Full Text] [Related]
4. Argyrophilic nucleolar organizer region in proliferating cell has a predictive value for local recurrence in superficial bladder tumor.
Tomobe M; Shimazui T; Uchida K; Hinotsu S; Akaza H
J Urol; 1999 Jul; 162(1):63-8. PubMed ID: 10379741
[TBL] [Abstract][Full Text] [Related]
5. Role of the argyrophilic nucleolar organizer regions in tumor detection and prognosis.
Pich A; Chiusa L; Margaria E
Cancer Detect Prev; 1995; 19(3):282-91. PubMed ID: 7750118
[TBL] [Abstract][Full Text] [Related]
6. Interphase argyrophilic nucleolar organiser regions and nucleolar counts in transitional cell bladder tumours.
Korneyev IA; Mamaev NN; Kozlov VV; Rybakova MG; al-Shukri SH
Mol Pathol; 2000 Jun; 53(3):129-32. PubMed ID: 10897331
[TBL] [Abstract][Full Text] [Related]
7. Two-dimensional agnor evaluation as a prognostic variable in urinary bladder carcinoma: a different approach via total agnor area/nucleus area per cell.
Cucer N; Imamoglu N; Tozak H; Demirtas H; Sarac F; Tatlisen A; Oztürk F
Micron; 2007; 38(6):674-9. PubMed ID: 17011198
[TBL] [Abstract][Full Text] [Related]
8. Nucleolar and argyrophilic nucleolar organizer region counts in urothelial carcinomas with special emphasis on grade II tumors.
Helpap B; Loesevitz L; Bulatko A
Virchows Arch; 1994; 425(3):265-9. PubMed ID: 7812512
[TBL] [Abstract][Full Text] [Related]
9. Ki-67 scores and AgNor counts in transitional cell carcinoma of the bladder: apparent lack of prognostic value.
Zambelli S; Zanin A; Gaglio A; Zai G; Bosco E; Andrion A; Magnani C
Arch Ital Urol Androl; 1993 Dec; 65(6):665-70. PubMed ID: 8312949
[TBL] [Abstract][Full Text] [Related]
10. [Significance of AgNOR analysis of urothelial carcinomas].
Helpap B; Loesevitz L
Verh Dtsch Ges Pathol; 1993; 77():222-5. PubMed ID: 7511285
[TBL] [Abstract][Full Text] [Related]
11. AgNOR count in resting cells (resting NOR) is a new prognostic marker in invasive bladder tumor.
Tomobe M; Shimazui T; Uchida K; Akaza H
Anal Cell Pathol; 2001; 22(4):193-9. PubMed ID: 11564895
[TBL] [Abstract][Full Text] [Related]
12. Argyrophilic nucleolar organizer region counts predict survival in thymoma.
Pich A; Chiarle R; Chiusa L; Palestro G
Cancer; 1994 Sep; 74(5):1568-74. PubMed ID: 7520349
[TBL] [Abstract][Full Text] [Related]
13. Comparative assessment of proliferating cell nuclear antigen immunostaining and of nucleolar organizer region staining in transitional cell carcinomas of the urinary bladder. Correlation with other conventional prognostic pathologic parameters.
Skopelitou A; Korkolopoulou P; Papanicolaou A; Christodoulou P; Thomas-Tsagli E; Pavlakis K
Eur Urol; 1992; 22(3):235-40. PubMed ID: 1361436
[TBL] [Abstract][Full Text] [Related]
14. AgNOR/P53 expression compared with different grades in bladder carcinoma.
Karakök M; Aydin A; Bakir K; Uçak R; Korkmaz C
Int Urol Nephrol; 2001; 33(2):353-5. PubMed ID: 12092655
[TBL] [Abstract][Full Text] [Related]
15. High and low risk prostate carcinoma determined by histologic grade and proliferative activity.
Chiusa L; Galliano D; Formiconi A; Di Primio O; Pich A
Cancer; 1997 May; 79(10):1956-63. PubMed ID: 9149023
[TBL] [Abstract][Full Text] [Related]
16. AgNOR counts and histological grade in stage pTa bladder tumours: reproducibility and relation to recurrence pattern.
Hansen AB; Bjerregaard B; Ovesen H; Horn T
Histopathology; 1992 Mar; 20(3):257-62. PubMed ID: 1563712
[TBL] [Abstract][Full Text] [Related]
17. Image analysis of Ag-NOR proteins in transitional cell bladder cancer.
Lipponen P
J Pathol; 1993 Dec; 171(4):279-83. PubMed ID: 8158457
[TBL] [Abstract][Full Text] [Related]
18. Silver-stained nucleolar organizer regions (AgNORs) as a prognostic value in malignant melanoma.
Barzilai A; Goldberg I; Yulash M; Pavlotsky F; Zuckerman A; Trau H; Azizi E; Kopolovic J
Am J Dermatopathol; 1998 Oct; 20(5):473-7. PubMed ID: 9790108
[TBL] [Abstract][Full Text] [Related]
19. Cathepsin B, p53 expression and AgNORs in transitional cell carcinoma.
Akpolat I; Bariş YS; Yilmaz AF; Bakirtaş M; Saylik A; Karagöz F; Kandemir B
Neoplasma; 1998; 45(6):365-8. PubMed ID: 10210109
[TBL] [Abstract][Full Text] [Related]
20. Flow cytometric DNA studies and AgNOR counts in patients with transitional cell carcinoma of the bladder.
Celikel C; Dillioğlugil O; Türkeri LN; Başaran M; Yalçiner A; Küllü S; Akdaş A
Eur Urol; 1995; 28(2):152-7. PubMed ID: 8529742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
